Literature DB >> 35788774

Prognostic value of lymph node ratio in resectable rectal cancer after preoperative short-course radiotherapy-results from randomized clinical trial.

Radoslaw Pach1, Antoni M Szczepanik2, Marek Sierzega2, Michal Daniluk3, Piotr Richter2.   

Abstract

PURPOSE: The value of the lymph node ratio (LNR) in patients with rectal cancer has not yet been unequivocally established. This study aims to assess the effect of the lymph node ratio on the prognosis of rectal cancer in patients operated after short-course preoperative 25 Gy radiotherapy, at 10-year follow-up.
METHODS: This is a substudy based on data from a prospective randomized clinical trial. A total of 141 patients with resectable rectal cancer were included. Lymph node yield was compared in patients with short and long time intervals between radiotherapy and surgery. Survival curves were compared between patients with different ypN and LNR categories. Univariate and multivariate analyses were performed to identify independent prognostic factors for overall survival and disease-free survival.
RESULTS: Survival and recurrence data were available for a median follow-up of 11.6 years. The lymph node yield did not differ significantly between the patients in the short- and long-interval groups. A greater difference in 10-year survival was observed in patients with LNR ≤ 0.41 and > 0.41 when compared to the ypN categories. Separate prognostic factor analyses were performed for the entire population and for subgroups that had < 12 and 12 lymph nodes resected. LNR was identified as an independent prognostic factor for overall survival, in multivariate analyses, for all patients and those with less than 12 retrieved lymph nodes.
CONCLUSION: The lymph node yield is comparable in patients with different time intervals between radiation therapy and surgery. LNR better discriminates patients in terms of overall survival than ypN categories. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT01444495, date of registration: September 30, 2011.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Disease-free survival; Lymph node ratio; Overall survival; Preoperative radiotherapy; Rectal cancer

Year:  2022        PMID: 35788774     DOI: 10.1007/s00423-022-02603-8

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  27 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

3.  Reduced lymph node yield in rectal carcinoma specimen after neoadjuvant radiochemotherapy has no prognostic relevance.

Authors:  Dietrich Doll; Ralf Gertler; Matthias Maak; Jan Friederichs; Karen Becker; Hans Geinitz; Monika Kriner; Hjalmar Nekarda; Jörg R Siewert; Robert Rosenberg
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

4.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Glynne-Jones; L Wyrwicz; E Tiret; G Brown; C Rödel; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

5.  Lymph node yield in rectal cancer surgery: effect of preoperative chemoradiotherapy.

Authors:  B Morcos; B Baker; M Al Masri; H Haddad; S Hashem
Journal:  Eur J Surg Oncol       Date:  2010-01-13       Impact factor: 4.424

6.  Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period.

Authors:  Robert Rosenberg; Jan Friederichs; Tibor Schuster; Ralf Gertler; Matthias Maak; Karen Becker; Anne Grebner; Kurt Ulm; Heinz Höfler; Hjalmar Nekarda; Jörg-Rüdiger Siewert
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

7.  Evaluation and comparison of the clinical, surgical and pathological TNM staging of colorectal cancer.

Authors:  Revekka Harisi; Zsuzsanna Schaff; Lajos Flautner; Tamas Winternitz; Balazs Jaray; Zsuzsanna Nemeth; Peter Kupcsulik; Janos Weltner
Journal:  Hepatogastroenterology       Date:  2008 Jan-Feb

8.  The value of lymph node ratio in the prediction of rectal cancer patient survival after preoperative chemoradiotherapy.

Authors:  Li Chen; Xuefeng Huang; Zhangfa Song
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

9.  Prognostic impact of at least 12 lymph nodes after neoadjuvant therapy in rectal cancer: A meta-analysis.

Authors:  Ling Tan; Zi-Lin Liu; Zhou Ma; Zhou He; Lin-Han Tang; Yi-Lei Liu; Jiang-Wei Xiao
Journal:  World J Gastrointest Oncol       Date:  2020-12-15

10.  Positive lymph node retrieval ratio optimises patient staging in colorectal cancer.

Authors:  S J Moug; J D Saldanha; J R McGregor; M Balsitis; R H Diament
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.